These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32140677)

  • 21. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.
    Loosen SH; Roderburg C; Kauertz KL; Koch A; Vucur M; Schneider AT; Binnebösel M; Ulmer TF; Lurje G; Schoening W; Tacke F; Trautwein C; Longerich T; Dejong CH; Neumann UP; Luedde T
    Sci Rep; 2017 Dec; 7(1):16975. PubMed ID: 29208940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T
    J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
    Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
    Gussen H; Hohlstein P; Bartneck M; Warzecha KT; Buendgens L; Luedde T; Trautwein C; Koch A; Tacke F
    J Intensive Care; 2019; 7():26. PubMed ID: 31061709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
    Sorio C; Mafficini A; Furlan F; Barbi S; Bonora A; Brocco G; Blasi F; Talamini G; Bassi C; Scarpa A
    BMC Cancer; 2011 Oct; 11():448. PubMed ID: 21999221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
    McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
    Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
    Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
    JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
    Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
    Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
    Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
    Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
    Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
    APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury.
    Zhang W; Gu Y; Zhou J; Wang J; Zhao X; Deng X; Li H; Yan L; Jiao X; Shao F
    Ren Fail; 2024 Dec; 46(1):2307959. PubMed ID: 38289005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.
    Yamashita S; Passot G; Aloia TA; Chun YS; Javle M; Lee JE; Vauthey JN; Conrad C
    Br J Surg; 2017 Feb; 104(3):267-277. PubMed ID: 28052308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.